Randomized Phase II Study of SGI-110 5 Days, Versus 5 Days + Idarubicin in Previously Untreated Patients >/= 70 Years With Acute Myeloid Leukemia

Trial Profile

Randomized Phase II Study of SGI-110 5 Days, Versus 5 Days + Idarubicin in Previously Untreated Patients >/= 70 Years With Acute Myeloid Leukemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Guadecitabine (Primary) ; Cladribine; Idarubicin
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Jun 2017 Results (n=34) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 24 Oct 2016 Status changed from active, no longer recruiting to recruiting.
    • 17 Oct 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top